个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhang Wen-Ji[1] * ; Li Yong[2] ; Wei Meng-Ning[1] ; Chen Yao[1] ; Qiu Jian-Ge[1] ; Jiang Qi-Wei[1] ; Yang Yang[1] ; Zheng Di-Wei[1] ; Qin Wu-Ming[1] ; Huang Jia-Rong[1] ; Wang Kun[1] ; Zhang Wen-Juan[3] ; Wang Yi-Jun[4] ; Yang Dong-Hua[4] ; Chen Zhe-Sheng[4，5,*1] ; Shi Zhi[1,*2] ;
机构： [1]Department of Cell Biology & Institute of Biomedicine, National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong 510632, China [2]Department of Gastrointestinal Surgery & General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China [3]Department of Preventive Medicine, College of Medicine, Jinan University, Guangzhou, Guangdong 510632, China [4]Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA [5]Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, 510632, PR China
出处：
DOI： 10.1016/j.canlet.2016.11.011
ISSN：

关键词： Regorafenib Lapatinib Targeted therapy Combination chemotherapy Colorectal cancer

摘要：
Regorafenib significantly prolongs overall survival in patients with metastatic colorectal cancer (mCRC), but the overall clinical efficacy of regorafenib remains quite limited. Combination chemotherapy is a potentially promising approach to enhance anticancer activity, overcome drug resistance, and improve disease-free and overall survival. The current study investigates the antitumor activity of regorafenib in combination with lapatinib in preclinical models of human CRC. Our results show improved antitumor efficacy when regorafenib is combined with lapatinib both in vitro and in vivo. Furthermore, pharmacokinetic analyses revealed that regorafenib and lapatinib do not influence on each plasma concentration. The finding that regorafenib in combination with lapatinib have synergistic activity warrants further clinical investigation of this beneficial combination as a potential treatment strategy for CRC patients. Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

基金：
NIH No. 1R15CA143701 and St. John's University Research Seed Grant No. 579-1110-7002 (Z.S.C), the National Natural Science Foundation of China No. 31271444, No. 81201726 (Z.S.) and No. 81473014 (W.J.Z.), the Science and Technology Program of Guangzhou No. 2014J4100009 (Z.S.), the Guangdong Natural Science Funds for Distinguished Young Scholar No. 2014A030306001 (Z.S.), the Guangdong Special Support Program for Young Talent No. 2015TQ01R350 (Z.S.), the Science and Technology Program of Guangdong No. 2016A050502027 (Z.S.), and the Foundation for Research Cultivation and Innovation of Jinan University No. 21616119 (Z.S.).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2016]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学
JCR分区：
出版当年[2015]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者：
第一作者机构： [1]Department of Cell Biology & Institute of Biomedicine, National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong 510632, China
通讯作者：
通讯机构： [1]Department of Cell Biology & Institute of Biomedicine, National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong 510632, China [4]Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA [5]Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, 510632, PR China [*1]8000 Utopia Parkway, Jamaica, NY 11439, USA. [*2]601 Huangpu Road West, Guangzhou, 510632, China.
推荐引用方式(GB/T 7714)：
Zhang Wen-Ji,Li Yong,Wei Meng-Ning,et al.Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.[J].CANCER LETTERS.2017,386:100-109.doi:10.1016/j.canlet.2016.11.011.
APA：
Zhang Wen-Ji,Li Yong,Wei Meng-Ning,Chen Yao,Qiu Jian-Ge...&Shi Zhi.(2017).Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer..CANCER LETTERS,386,
MLA：
Zhang Wen-Ji,et al."Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.".CANCER LETTERS 386.(2017):100-109

相关文献

[1]Comprehensive analysis identifies novel targets of gemcitabine to improve chemotherapy treatment strategies for colorectal cancer [2]Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer [3]Signaling pathways in rheumatoid arthritis: implications for targeted therapy [4]Developing liver-targeted naringenin nanoparticles for breast cancer endocrine therapy by promoting estrogen metabolism [5]腹腔镜结直肠癌根治术联合大范围肝切除术治疗结直肠癌肝转移 [6]Piezo1 activation accelerates osteoarthritis progression and the targeted therapy effect of artemisinin [7]pH-responsive black phosphorus quantum dots for tumor-targeted photodynamic therapy. [8]百普素应用于结直肠癌围手术期病人的临床观察 [9]Targeted therapy with anlotinib for a leptomeningeal spread recurrent glioblastoma patient. [10]Black Phosphorus Nanosheets Induced Oxidative Stress In Vitro and Targeted Photo-thermal Antitumor Therapy

资源点击量：2021 今日访问量：0 总访问量：646 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号